{
  "document_id": "HOUSE_OVERSIGHT_024102",
  "filename": "IMAGES-007-HOUSE_OVERSIGHT_024102.txt",
  "text": "Sprout Capital IX, L.P. (Healthcare Technology Portfolio)\n$ amounts in millions, as of March 31, 2014\nPlease refer to Endnotes 1,],K,L,M and N in this Appendix.\n\nGross\nMultiple\nTotal\nValue\n\nRealized Unrealized\nValue Value\n\nTotal\nCost\n\nVintage\n\nCompany Sector Year Portion)\n\nGross\n\n(Realized Multiple\n\n(Total)\n\nGross IRR\n\nRealize Partially Realized Investments\n\nAdolor Corporation Therapeutics 29.3\n\nAffymax, Inc. Therapeutics 2001 B72 17.9 - 17.9 0.48\nAspire Medical Healthcare Devices 2004 7A 0.6 - 0.6 0.07\nAspreva Pharmaceuticals Therapeutics 2004 23.2 151.7 - 151.7 6.54\nAureon Biosciences, Inc. Diagnostics & Infrastructure 2001 34.1 0.8 - 0.8 0.02\nAuxilium Pharmaceuticals, Inc. Therapeutics 2003 23.1 106.3 - 106.3 4.60\nCorixa Corporation. Therapeutics 2003 42.7 31.1 - 31.1 0.73\neHealth, Inc. Convergence 2001 12.1 58.4 - 58.4 4.83\nEpicor Medical, Inc. Healthcare Devices 2001 93 41.8 - 41.8 4.49\nePocrates, Inc. Convergence 2000 17.2 53.2 - 53.2 3.10\nFocus Technologies, Inc. Diagnostics & Infrastructure 2000 32.3 84.1 - 84.1 2.61\nGryphon Therapeutics Therapeutics 2002 13.3 0.2 - 0.2 0.01\nIlypsa, Inc. (fka Symyx) Therapeutics 2003 15.8 109.4 - 109.4 6.91\nISTA Pharmaceuticals, Inc. Therapeutics 2002 42.9 84.6 - 84.6 1.97\nKalypsys Therapeutics 2002 27.4 1.1 - 11 0.05\nLathian Systems, Inc Convergence 2001 7.1 0.0 - 0.0 0.00\nMetabasis Therapeutics, Inc. Therapeutics 2001 23.8 11 - 1.1 0.05\nNeuroVista Corp. Healthcare Devices 2004 8.8 - - - -\nNxStage Medical, Inc. Healthcare Devices 2001 21.6 45.1 - 45.1 2.09\nNyco Holdings ApS Therapeutics 2002 47.0 222.8 2.7 2955 4,74\nPharsight Corporation Convergence 2002 2.8 6.4 - 6.4 2.31\nPhylos, Inc. Therapeutics 2000 10.2 - - - -\nProgen Pharmalnc. (Cellgate) Therapeutics 2003 21.4 0.4 - 0.4 0.02\nProtedyne Corporation Diagnostics & Infrastructure 2001 21.9 3.7 - 3.7 0.17\nRadiant Medical, Inc. Healthcare Devices 2000 18.6 0.5 - 0.5 0.02\nSirna Therapeutics, Inc. Therapeutics 2003 27.2 219.3 - 219.3 8.06\nSpiration, Inc. Healthcare Devices 2002 17.4 14.5 - 14.5 0.84\nTolerx, Inc. Therapeutics 2002 11.0 1.5 - 1.5 0.14\nTriple Point Healthcare Devices 2004 0.3 0.1 - 0.1 0.28\nVascA, Inc. Healthcare Devices 2001 12.8 0.4 - 0.4 0.03\nVisiogen, Inc. Healthcare Devices 2001 17.9 90.0 - 90.0 5.04\nVNUS Medical Technologies, Inc. Healthcare Devices 2001 8.0 22.1 - 22.1 2.76\nTotal Realized or Partially Realized Investments $ 645.0 $ 1,392.4 $ 2.7 $ 1,395.1 2.18\nUnrealized Investments\n\nExpression Diagnostics (XDx) Diagnostics & Infrastructure 2004 $ 166 $ 0.0 6$ 3.8 ¢ 3.8 NA\nIntrinsic Therapeutics, Inc. Healthcare Devices 2002 $ 266 $ 0.0 6$ = $ 0.0 NA\nLabcyte, Inc. (fka Picoliter) Diagnostics & Infrastructure 2002 $§$ 10.0 $ 2 $ 10.6 $ 10.6 NA\nRelypsa, Inc. Therapeutics 2007 § 203 $ 0.0 6$ 504 $ 50.4 NA\nSopherion Therapeutics, Inc. Therapeutics 2004 §$ 151 $ - $ 0.0 6$ 0.0 NA\nSpinewave Healthcare Devices 2004 § 105 $ * $ 3.7 $ 3.7 NA\nTotal Unrealized Investments $ 991 $ 0.0 $ 68.4 §$ 68.4 =\n\n0.48\n0.07\n6.54\n0.02\n4.60\n0.73\n4.83\n4.49\n3.10\n2.61\n0.01\n6.91\n1.97\n0.04\n0.00\n0.05\n\n2.09\n4.80\n2.31\n\n0.02\n0.17\n0.02\n8.06\n0.84\n0.14\n0.28\n0.03\n5.04\n2.76\n\n2.16\n\n0.23\n0.00\n1.06\n2.49\n0.00\n0.35\n\n0.69\n\noL13 76\nNM\n95.4%\nNM\n37.4%\n-13.2%\n26.8%\n78.7%\n10.8%\n17.8%\n-60.7 %\n78.0%\n10.8%\n229.7 %s\nNM\nNM\nNM\n9.4%\n33.6%\n16.2%\nNM\n-49.9%\nNM\nNM\n91.0%\n-2.4%\n-23.0 %\n-48.3 %\nNM\n35.4%\n15.4%\n\n16.8%\n\n-19.4%\nNM\n0.5%\n\n23.9%\nNM\n\n-11.9%\n\n-5.0%\n\n91\n\nCONTROL NUMBER 257 - CONFIDENTIAL\n\nHOUSE_OVERSIGHT_024102",
  "metadata": {
    "original_filename": "IMAGES-007-HOUSE_OVERSIGHT_024102.txt",
    "source_dataset": "huggingface:tensonaut/EPSTEIN_FILES_20K",
    "character_count": 3427,
    "word_count": 570,
    "line_count": 166,
    "import_date": "2025-11-19T21:47:48.522495",
    "prefix": "IMAGES-007"
  }
}